Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-hodgkin lymphoma patients undergoing curative-intent r-chop chemotherapy

HIGHLIGHTS

• who: Xiao Jun Wang and colleagues from the Department of, University of Singapore, Singapore, Singapore, Department of have published the article: Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy, in the Journal: PLOS ONE | DOI:10.1371/journal.pone [0148901]. February 12, 2016 of January/24,/2016
• what: The aim of this study was to compare the cost-effectiveness of primary and secondary prophylaxis with biosimilar filgrastim (nivestim), pegfilgrastim, or no prophylaxis to reduce . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.